09/08/2026
We have a safety study of BPC-157 in dogs, but safety is only one part of the picture.
A pharmacokinetics study helps answer a completely different question:
What does the dog’s body actually DO with BPC-157?
How quickly is it absorbed?
How much reaches circulation?
How long does the intact peptide remain in the bloodstream?
How is it metabolized and eliminated?
In beagle dogs, BPC-157 was absorbed rapidly after intramuscular injection, reaching peak blood concentrations within minutes.
The intact peptide also had a very short plasma half-life.
However, a short plasma half-life does NOT automatically mean a short biological effect.
Pharmacokinetics tells us how long the intact compound is measurable in circulation. It does not, by itself, tell us how long the downstream biological effects continue.
And while this study gives us some extremely useful information, we still have major gaps, especially for routes like subcutaneous and oral administration.
This is exactly why veterinary specific research matters.
We should not have to rely entirely on extrapolating from humans when we can actually study what happens in dogs.
Study:
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182.